Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
HAEMONETICS CORP incurred credit facility of $250 million senior unsecured term loan with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% maturing April 30, 2029.
- Instrument
- credit facility
- Principal
- $250 million senior unsecured term loan
- Counterparty
- JPMorgan Chase Bank, N.A., as administrative agent
- Rate
- Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750%
- Maturity
- April 30, 2029
- Event
- incurrence
Exact text from the filing
The Revised Credit Agreement provides for a $250 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2022 Credit Agreement, and a $750 million senior unsecured revolving credit facility, which constitutes a $330 million increase from the revolving credit facility under the 2022 Credit Agreement.
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
HAEMONETICS CORP incurred revolving credit of $750 million senior unsecured revolving credit facility with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% maturing April 30, 2029.
- Instrument
- revolving credit
- Principal
- $750 million senior unsecured revolving credit facility
- Counterparty
- JPMorgan Chase Bank, N.A., as administrative agent
- Rate
- Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750%
- Maturity
- April 30, 2029
- Event
- incurrence
Exact text from the filing
The Revised Credit Agreement provides for a $250 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2022 Credit Agreement, and a $750 million senior unsecured revolving credit facility, which constitutes a $330 million increase from the revolving credit facility under the 2022 Credit Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
HAEMONETICS CORP amended Revised Credit Agreement with JPMorgan Chase Bank, N.A. valued at $250 million senior unsecured term loan (effective 2024-04-30).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- JPMorgan Chase Bank, N.A.
- Value
- $250 million senior unsecured term loan
- Effective
- 2024-04-30
Exact text from the filing
On April 30, 2024, Haemonetics Corporation (the “Company”) entered into a second amended and restated credit agreement by and among the Company, as borrower, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Revised Credit Agreement”).
View on SEC.gov